Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Eur J Cancer ; 40(8): 1233-43, 2004 May.
Article in English | MEDLINE | ID: mdl-15110888

ABSTRACT

Analyses of data from cancer registries have shown a 10% unit difference in 5-year relative survival between Danish and Swedish patients with breast cancer. This study investigates the effect of age and patho-anatomic variables on this survival difference. Hospital records were collected for women over 40 years of age diagnosed in 1989 or 1994 in east Denmark and south Sweden; patho-anatomical variables and survival were compared between 2289 Danish and 1715 Swedish women. Tumours were smaller, node-negative axillae more frequent and well-differentiated tumours almost 10% more frequent in Sweden. A superior 5-year relative survival in Sweden was found in the 50- to 79-year age group. The adjusted hazard rate ratio between countries was 1.7 in 1989 and 1.3 in 1994. Conditional survival after surviving the first 5 years was similar for the two countries. Adjusting for patho-anatomical variables reduced but did not eliminate the higher risk of death among the Danish patients. Higher population death rates could explain some but not all of the residual elevated risk for Danish women.


Subject(s)
Breast Neoplasms/mortality , Age of Onset , Breast Neoplasms/pathology , Denmark/epidemiology , Epidemiologic Methods , Female , Humans , Prognosis , Sweden/epidemiology
2.
Diabetologia ; 47(5): 878-84, 2004 May.
Article in English | MEDLINE | ID: mdl-15095040

ABSTRACT

AIMS/HYPOTHESIS: Gestational diabetes mellitus is a heterogeneous disorder characterised by impaired insulin secretion and action. Our aim was to study whether autoimmunity, variations in genes affecting insulin secretion and action, or both, contribute to the development of gestational diabetes and whether the pathogenesis of the disease differs between women with a Scandinavian or Arabian background. METHODS: We studied a total of 500 unrelated women with gestational diabetes (400 Scandinavian and 100 Arabian) and 550 unrelated pregnant non-diabetic control women (428 Scandinavian and 122 Arabian) matched for ethnicity. RESULTS: Arabian women with gestational diabetes were 50% more insulin resistant for the same BMI compared with Scandinavian women with the disease (homeostasis model assessment [HOMA-IR]; 3.2+/-0.3 vs 2.2+/-0.2, p=0.02). Both Scandinavian (4.2% vs 0.9%, p=0.008) and Arabian (4.6% vs 0.0%, p=0.03) women with gestational diabetes had a higher frequency of GAD antibodies (GAD65Ab) than the matched controls. The frequency of HLA-DQB1 risk genotypes was slightly higher in Scandinavian women with gestational diabetes than in the Scandinavian controls (46.3% vs 38.8%, p=0.03) but no significant difference was found between the Arabian women with gestational diabetes and the Arabian controls (47% vs 51.6%, p=0.47). There were no significant differences in the frequency of the insulin gene variable number of tandem repeat ( INS VNTR) alleles and genotypes or the peroxisome proliferator-activated receptor-gamma 2 ( PPAR gamma 2-Pro12Ala) polymorphism between the women with gestational diabetes and the control women either in Arabian or in Scandinavian women. CONCLUSIONS/INTERPRETATION: Gestational diabetes mellitus was associated with the presence of GAD65Ab in both study groups. Scandinavian women with gestational diabetes may share some genetic features with Type 1 diabetes. In addition, Arabian women with gestational diabetes are more insulin resistant than Scandinavian women with gestational diabetes and with the same BMI.


Subject(s)
Diabetes, Gestational/genetics , Adult , Amino Acid Substitution , Arabs , Autoantibodies/blood , Blood Glucose/metabolism , Diabetes, Gestational/immunology , Ethnicity , Female , Glutamate Decarboxylase/immunology , Humans , Insulin/blood , Isoenzymes/immunology , Polymorphism, Single Nucleotide/genetics , Pregnancy , Scandinavian and Nordic Countries , White People
3.
BMC Cancer ; 3: 11, 2003 Apr 09.
Article in English | MEDLINE | ID: mdl-12697074

ABSTRACT

BACKGROUND: Patients with possible radiation induced cancer could be used to study if the rate of tumour cell proliferation is related to latency time. Such a finding could help researcher to find time periods when other initiating risk factors operate. METHODS: Seventeen women with breast cancer, with a prior history of radiation treatment towards the parts or the whole breast, exclusive of the primary treatment of a breast cancer were identified. Most women had received treatment for benign disorders as hemangiomas, shoulder pain or skin infections. Three patients had been treated with mantle radiation for Hodgkin's disease prior to developing breast cancer. DNA analysis were performed, on remaining tumour tissue after hormone receptor analysis had been done, measuring the fraction of tumour cells in S-phase. Latency time (time between diagnosis and previous radiation treatment) was calculated and related to the S-phase fraction. RESULTS: A significant inverse relationship between latency time and S-phase was found (p < 0.0025), indicating that tumours with a high S-phase had a short latency time and vice versa. Among the possible radiation induced tumours, median S-phase was 14%, comparable with a median latency time of 22 years. Very high S-phase values were associated with short latency times (eg a S-phase of 35% would be compatible with a latency time of 7 years). CONCLUSION: Our preliminary results indicate that S-phase is related to latency time and that the median latency time maybe as long as 22 years. Our data may also explain why breast cancer is rare before 30 years of age and if patients are diagnosed at early ages, tumours often show high S-phase values and bad prognostic signs. We postulate that these results from radiation induced breast cancer may be used to extrapolate possible latency times in patients with non radiation induced breast tumours in order to isolate possible time periods for research after other initiating events.


Subject(s)
Breast Neoplasms/etiology , Neoplasms, Radiation-Induced/etiology , Adult , Aged , Breast Neoplasms/pathology , Cell Division , Female , Humans , Middle Aged , Neoplasms, Radiation-Induced/pathology , Radiation, Ionizing , S Phase , Time Factors
4.
Oral Oncol ; 38(7): 706-13, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12167424

ABSTRACT

Salivary gland carcinomas demonstrate a wide diversity of histopathological types and biological behavior. The aim of this study was to analyze relative survival of patients with major salivary gland carcinomas with special reference to histopathology, gender and age. All new carcinomas of the major salivary glands reported to the National Swedish Cancer Registry 1960-1995 were searched for and the vital status of the cases was updated by record linkage to the Swedish Population Registry through December 31 1996. The study comprised 2465 patients with carcinoma of the parotid or submandibular glands. Relative survival differed markedly according to histopathological typing (P<0.001). For parotid tumors, acinic cell carcinomas had the best prognosis with a 10-year relative survival of 88%. The corresponding figures for mucoepidermoid carcinomas, adenoidcystic carcinomas and carcinoma ex pleomorphic adenoma were 80, 74 and 73%. Adenocarcinoma NOS and undifferentiated carcinoma had worse prognosis, with 10-year relative survival of 55 and 44%. Patients with submandibular gland cancer had similar relative survival to those with parotid cancers, besides those with mucoepidermoid cancer and adenocarcinoma NOS, who carried worse prognosis. Age and gender had an impact on relative survival for patients with mucoepidermoid carcinoma, adenocarcinoma and undifferentiated cancer of the parotid.


Subject(s)
Parotid Neoplasms/mortality , Submandibular Gland Neoplasms/mortality , Adolescent , Adult , Age Distribution , Aged , Aged, 80 and over , Child , Child, Preschool , Female , Humans , Infant , Male , Middle Aged , Parotid Neoplasms/epidemiology , Parotid Neoplasms/pathology , Sex Distribution , Submandibular Gland Neoplasms/epidemiology , Submandibular Gland Neoplasms/pathology , Sweden/epidemiology
5.
Acta Oncol ; 40(4): 491-6, 2001.
Article in English | MEDLINE | ID: mdl-11504309

ABSTRACT

The prognostic value of histopathological response to preoperative radiotherapy (50 Gy) in radically resected oral carcinomas was studied in 39 consecutive patients. Microvessel density (MVD) was evaluated for relation to radioresponse and outcome. Resected tumour tissue was examined histopathologically and response to radiotherapy was scored according to induced morphological changes. Pretreatment biopsies were stained with antibodies to von Willebrand factor to evaluate MVD in hot-spot regions, in stromal tissue and in tumour epithelial tissue. Histopathological response to radiotherapy was highly prognostic of local failures and survival (p = 0.002), though microscopic surgical radicality was obtained. In good responders to preoperative radiotherapy, the 5-year survival rate was 68% compared with 24% in poor responders. In 12 patients with local recurrence after radical surgery, 11 had poor histopathological radiotherapy responses. In univariate analysis, a high MVD score in tumour epithelium was associated with poor clinical outcome but MVD did not correlate with histopathological radiotherapy response.


Subject(s)
Carcinoma, Squamous Cell/radiotherapy , Mouth Mucosa/radiation effects , Mouth Neoplasms/radiotherapy , Neovascularization, Pathologic/pathology , Radiotherapy, High-Energy , Adult , Aged , Carcinoma, Squamous Cell/blood supply , Carcinoma, Squamous Cell/drug therapy , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/surgery , Cell Hypoxia , Chemotherapy, Adjuvant , Cobalt Radioisotopes/therapeutic use , Combined Modality Therapy , Disease-Free Survival , Dose Fractionation, Radiation , Epithelial Cells/radiation effects , Female , Humans , Life Tables , Lymphatic Metastasis , Male , Middle Aged , Mouth Neoplasms/blood supply , Mouth Neoplasms/drug therapy , Mouth Neoplasms/pathology , Mouth Neoplasms/surgery , Neoadjuvant Therapy , Neoplasm Recurrence, Local , Prognosis , Radiation Tolerance , Radioisotope Teletherapy , Radiotherapy Planning, Computer-Assisted , Radiotherapy, Adjuvant , Stromal Cells/radiation effects , Survival Analysis , Survival Rate , Treatment Outcome
6.
J Clin Oncol ; 19(13): 3173-81, 2001 Jul 01.
Article in English | MEDLINE | ID: mdl-11432883

ABSTRACT

PURPOSE: To assess the risk of death in patients who survive more than 5 years after diagnosis of childhood cancer and to evaluate causes of death in fatal cases. PATIENTS AND METHODS: This was a population-based study in the five Nordic countries (Denmark, Finland, Iceland, Norway, and Sweden) using data of the nationwide cancer registries and the cause-of-death registries. The study cohort included 13,711 patients who were diagnosed with cancer before the age of 20 years between 1960 and 1989 and who survived at least 5 years from diagnosis. By December 31, 1995, 1,422 patients had died, and death certificates were assessed in 1,402. Standardized mortality ratios (SMRs) for validated causes of death were calculated based on 156,046 patient-years at risk. RESULTS: The overall SMR was 10.8 (95% confidence interval [CI], 10.3 to 11.5), mainly due to high excess mortality from the primary cancer. SMR for second cancer was 4.9 (95% CI, 3.9 to 5.9) and was 3.1 (95% CI, 2.8 to 3.5) for noncancer death. The pattern of causes of death varied markedly between different groups of primary cancer diagnoses and was highly dependent on time passed since diagnosis. Overall late mortality was significantly lower in patients treated during the most recent period of time, 1980 to 1989, compared with those treated from 1960 to 1979 (hazard ratio, 0.61; 95% CI, 0.54 to 0.70), and there was no increase in rates of death due to cancer treatment. CONCLUSION: Long-term survivors of childhood cancer had an increased mortality rate, mainly dying from primary cancers. However, modern treatments have reduced late cancer mortality without increasing the rate of therapy-related deaths.


Subject(s)
Neoplasms/mortality , Adolescent , Adult , Age of Onset , Cause of Death , Child , Child, Preschool , Cohort Studies , Female , Finland/epidemiology , Humans , Iceland/epidemiology , Infant , Infant, Newborn , Male , Neoplasms/complications , Neoplasms/therapy , Proportional Hazards Models , Risk , Scandinavian and Nordic Countries/epidemiology , Survival Analysis , Time Factors
7.
Am J Ind Med ; 39(1): 19-28, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11148012

ABSTRACT

BACKGROUND: The aim of the study was to evaluate whether cadmium concentrations in kidney (K-Cd), blood (B-Cd) or urine (U-Cd) could reveal previous occupational cadmium exposure at a metal smelter. METHODS: The study included 90 smelters and 35 controls (B-Cd and U-Cd determination). In a subgroup (N = 33), K-Cd was also determined. RESULTS: B-Cd (median 4.6; range 0.5-53 nmol/L), U-Cd (0. 29; 0.04-1.9 micromol/mol creatinine) and K-Cd (14; 3-61 microg/g wet weight) were similar to reported concentrations in the general Swedish population. In the subgroup, significant associations (P<0. 001) were obtained between B-Cd and K-Cd (r = 0.70), U-Cd and K-Cd (r = 0.60) and between U-Cd and B-Cd (r = 0.62). Multiple regression analyses revealed smoking as the major predictor of K-Cd, B-Cd, and U-Cd. B-Cd and U-Cd were both associated with the duration of employment at the smelter. CONCLUSIONS: There was no statistically significant evidence of previous occupational exposure at the smelter from measurement of K-Cd.


Subject(s)
Cadmium/analysis , Kidney/metabolism , Metallurgy , Occupational Exposure , Adult , Age Factors , Aged , Analysis of Variance , Bone and Bones/metabolism , Cadmium/blood , Cadmium/urine , Confidence Intervals , Creatinine/urine , Employment , Forecasting , Humans , Lead/analysis , Lead/blood , Linear Models , Male , Middle Aged , Smoking , Spectrometry, X-Ray Emission , Sweden , Time Factors
8.
Eur J Surg ; 167(10): 748-57, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11775726

ABSTRACT

OBJECTIVE: To see whether there was an increasing incidence of adenocarcinoma of the oesophagus and gastric cardia in the Swedish population. If there is a rising trend and variations in it can be found, could it be explained as a period or cohort phenomenon? The data were also compared with the incidence of squamous cell carcinoma and gastric cancer with the gastric cardia excluded. DESIGN: Retrospective study. SETTING: Sweden. SUBJECTS: Swedish population. MAIN OUTCOME MEASURES: Age standardised incidence for each sex was calculated using the age distribution of the world population as a reference. Age-period-cohort models were fitted to data using Poisson regression to model log incidence rates. RESULTS: For the combined group of adenocarcinoma in the oesophagus and gastric cardia age standardised incidence gradually increased during the study period. The median increase between adjacent five-year intervals was 20% in women and 14% in men. A period effect was evident in men. CONCLUSION: This study shows that the incidence of adenocarcinoma of the oesophagus and gastroesophageal junction is rising for both men and women in the Swedish population. This is explained as a period effect. As well as previously-described risk factors such as gastro-oesophageal reflux, obesity, and smoking, the increasing incidence can be explained as a shift in classification from squamous cell carcinoma to adenocarcinoma after 1985.


Subject(s)
Adenocarcinoma/epidemiology , Esophageal Neoplasms/epidemiology , Stomach Neoplasms/epidemiology , Adenocarcinoma/diagnosis , Adult , Age Distribution , Aged , Aged, 80 and over , Cohort Studies , Confidence Intervals , Esophageal Neoplasms/diagnosis , Esophagogastric Junction/pathology , Female , Humans , Male , Middle Aged , Prevalence , Probability , Retrospective Studies , Risk Factors , Sex Distribution , Stomach Neoplasms/diagnosis , Survival Analysis , Sweden/epidemiology
9.
Br J Cancer ; 80(11): 1809-14, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10468301

ABSTRACT

In a study based on formalin-fixed paraffin-embedded material from 86 patients with primary synovial sarcoma located in the extremities or on the trunk wall, the prognostic importance of MIB-1 index, p53-expession and tumour size was analysed. Multivariate analysis identified two metastatic risk factors: increasing tumour size and MIB-1 > 9%. The 5-year metastasis-free survival-rate for patients with tumour size < or = 5 cm + MIB-1 < 10% was 0.83 (95% confidence interval (CI) 0.64-0.92) compared to 0.31 (95% CI 0.11-0.53) in cases with tumour size > 5 cm + MIB-1 > or = 10%. Our study shows that metastatic disease in synovial sarcoma is closely related to MIB-1 index. Using our model based on tumour size and MIB-1 index, cases with good and poor prognosis can easily be discriminated. Therefore our model can be used to identify patients who should be considered for adjuvant chemotherapy.


Subject(s)
Ki-67 Antigen/analysis , Sarcoma, Synovial/mortality , Sarcoma, Synovial/pathology , Antigens, Nuclear , Biomarkers/analysis , Cell Nucleus/pathology , Confidence Intervals , Disease-Free Survival , Humans , Mitotic Index , Multivariate Analysis , Neoplasm Metastasis , Nuclear Proteins/analysis , Prognosis , Proportional Hazards Models , Registries , Retrospective Studies , Scandinavian and Nordic Countries/epidemiology , Survival Analysis , Tumor Suppressor Protein p53/analysis
10.
Cancer Res ; 59(13): 3180-4, 1999 Jul 01.
Article in English | MEDLINE | ID: mdl-10397263

ABSTRACT

Cytogenetically, synovial sarcoma (SS) is characterized by the translocation t(X;18)(p11.2;q11.2), resulting in a fusion between the SYT gene on chromosome 18 and SSX1 or SSX2 on the X chromosome and the formation of new chimeric genes, SYT-SSX1 or SYT-SSX2. We examined the potential clinical relevance of SYT-SSX1 and SYT-SSX2 fusion transcripts together with tumor proliferation. In a series of 33 patients with primary SS, the type of fusion transcript was assessed by reverse transcription-PCR and sequence analysis. The proliferation rate was analyzed using anti-Ki-67 antibodies. One case carrying an atypical transcript with a 57-bp insert was excluded, leaving 13 SYT-SSX1 and 19 SYT-SSX2 cases for analysis. The hazard ratio (with respect to metastasis-free survival for patients with SYT-SSX1 versus patients with SYT-SSX2 fusion transcripts was 7.4 (95% confidence interval, 1.5-36; log-rank P = 0.004). There was also an association with reduced overall survival for patients with SYT-SSX1 compared to patients with SYT-SSX2 (hazard ratio, 8.5; 95% confidence interval, 1.0-73; log-rank P = 0.02). The 5-year metastasis-free survival for patients with SYT-SSX1 was 42% versus 89% for patients with SYT-SSX2. There was a significant association between SYT-SSX1 and a high tumor proliferation rate (P = 0.02). We conclude that the findings suggest that the type of SYT-SSX fusion transcript determines the proliferation rate and is an important predictor of clinical outcome in patients with SS.


Subject(s)
Genetic Variation , Oncogene Proteins, Fusion/genetics , Sarcoma, Synovial/genetics , Adolescent , Adult , Aged , Base Sequence , Biomarkers, Tumor/genetics , Cell Division , Child , Chromosome Mapping , Chromosomes, Human, Pair 18 , Disease-Free Survival , Female , Humans , Male , Middle Aged , Molecular Sequence Data , Predictive Value of Tests , Sarcoma, Synovial/mortality , Sarcoma, Synovial/pathology , Sequence Alignment , Survival Rate , Translocation, Genetic , Treatment Outcome , X Chromosome
11.
Acta Orthop Scand ; 70(6): 536-42, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10665716

ABSTRACT

We analyzed treatment and outcome in 104 Scandinavian patients with synovial sarcoma in the extremities or trunk wall, diagnosed between 1986 and 1994. Only surgically treated patients without metastases at diagnosis were included. Median follow-up of survivors was 6 (3-11) years. 34 patients developed metastases. The overall 5- and 7-year survival rates were 0.76 (95% CI 0.66-0.83) and 0.69 (0.58-0.78), respectively. Large tumor size and amputation were significantly associated with impaired metastasis-free survival. Patients with local recurrence had a higher risk of metastases following the local event. Local excision with inadequate margin was associated with a higher risk of local recurrence.


Subject(s)
Sarcoma, Synovial/surgery , Adolescent , Adult , Aged , Aged, 80 and over , Child , Female , Follow-Up Studies , Humans , Male , Middle Aged , Neoplasm Recurrence, Local , Prognosis , Proportional Hazards Models , Sarcoma, Synovial/mortality , Sarcoma, Synovial/secondary , Survival Rate
12.
Acta Orthop Scand ; 70(6): 543-54, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10665717

ABSTRACT

Synovial sarcoma has traditionally been regarded as a high-grade sarcoma and treated as such. Recently, specific types of poorly differentiated synovial sarcoma have been defined and shown to affect prognosis adversely. We studied 104 primary synovial sarcomas of the extremities and trunk wall without metastasis at diagnosis that were retrieved from the Scandinavian Sarcoma Group Registry (SSG) and the Swedish Cancer Registry from 1986 to 1994. Follow-up was available in all patients, median 6 (3-11) years for the survivors. There were local recurrences in 15% of patients and metastases in 33%. Histologically, the tumors were divided into favorable and unfavorable types. The favorable type had no significant cytologic atypia, and in most instances, no necrosis and a mitotic count of < 10/10 hpf. The unfavorable type included so-called poorly differentiated synovial sarcomas as well as recognizable biphasic and monophasic synovial sarcomas with prominent nuclear atypia, extreme cellularity and nuclear crowding. Designation of a tumor as having favorable vs. unfavorable histology conveyed more prognostic information than any single histologic factor. Kaplan-Meier estimates of metastasis-free survival at 5 years were 83% for patients with histologically favorable tumors and 31% for patients with histologically unfavorable tumors (95% confidence intervals 72-92% and 13-51%, respectively). These findings may influence future treatment protocols for synovial sarcoma.


Subject(s)
Sarcoma, Synovial/pathology , Adolescent , Adult , Aged , Aged, 80 and over , Child , Female , Humans , Male , Middle Aged , Prognosis , Proportional Hazards Models , Sarcoma, Synovial/classification , Sarcoma, Synovial/mortality , Survival Rate
SELECTION OF CITATIONS
SEARCH DETAIL
...